Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M51,143Revenue $M20,272Net Margin (%)13.6Altman Z-Score2.0
Enterprise Value $M58,805EPS $3.6Operating Margin %18.4Piotroski F-Score8
P/E(ttm)18.9Beneish M-Score-2.8Pre-tax Margin (%)16.3Higher ROA y-yY
Price/Book2.310-y EBITDA Growth Rate %14.6Quick Ratio0.9Cash flow > EarningsY
Price/Sales2.65-y EBITDA Growth Rate %4.8Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow15.8y-y EBITDA Growth Rate %104ROA % (ttm)5.9Higher Current Ratio y-yY
Dividend Yield %2.2PEG4.0ROE % (ttm)11.9Less Shares Outstanding y-yN
Payout Ratio %43.0Shares Outstanding M848ROIC % (ttm)9.6Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAGeorge Soros 2015-03-31 Sold Out -3.1%$54.93 - $62.65
($58.14)
$ 60.274%Sold Out0
TEVAVanguard Health Care Fund 2015-03-31 Reduce-0.41%$54.93 - $62.65
($58.14)
$ 60.274%Reduce 61.47%1,896,960
TEVAFirst Eagle Investment 2015-03-31 Add0.26%$54.93 - $62.65
($58.14)
$ 60.274%Add 71.77%4,205,481
TEVANWQ Managers 2015-03-31 Reduce-0.24%$54.93 - $62.65
($58.14)
$ 60.274%Reduce 8.53%3,669,079
TEVADavid Dreman 2015-03-31 Reduce-0.09%$54.93 - $62.65
($58.14)
$ 60.274%Reduce 16.44%100,133
TEVAMichael Price 2015-03-31 Reduce-0.05%$54.93 - $62.65
($58.14)
$ 60.274%Reduce 1.61%440,300
TEVAJames Barrow 2015-03-31 Reduce-0.05%$54.93 - $62.65
($58.14)
$ 60.274%Reduce 5.85%10,189,904
TEVARonald Muhlenkamp 2015-03-31 Add$54.93 - $62.65
($58.14)
$ 60.274%Add 0.18%176,710
TEVAJohn Keeley 2015-03-31 Reduce$54.93 - $62.65
($58.14)
$ 60.274%Reduce 2.95%36,835
TEVATom Gayner 2014-12-31 Sold Out -0.67%$49.86 - $58.72
($55.72)
$ 60.278%Sold Out0
TEVAGeorge Soros 2014-12-31 Reduce-0.55%$49.86 - $58.72
($55.77)
$ 60.278%Reduce 22.01%4,859,966
TEVANWQ Managers 2014-12-31 Reduce-0.39%$49.86 - $58.72
($55.72)
$ 60.278%Reduce 14.62%4,011,187
TEVAMichael Price 2014-12-31 Reduce-0.36%$49.86 - $58.72
($55.77)
$ 60.278%Reduce 10.50%447,500
TEVADavid Dreman 2014-12-31 Reduce-0.16%$49.86 - $58.72
($55.77)
$ 60.278%Reduce 23.89%119,838
TEVAFirst Eagle Investment 2014-12-31 Add0.14%$49.86 - $58.72
($55.72)
$ 60.278%Add 72.35%2,448,310
TEVAVanguard Health Care Fund 2014-12-31 Reduce-0.06%$49.86 - $58.72
($55.76)
$ 60.278%Reduce 8.19%4,923,200
TEVAJames Barrow 2014-12-31 Add0.03%$49.86 - $58.72
($55.76)
$ 60.278%Add 4.37%10,823,115
TEVAJohn Keeley 2014-12-31 Reduce-0.01%$49.86 - $58.72
($55.72)
$ 60.278%Reduce 20.45%37,955
TEVARonald Muhlenkamp 2014-12-31 Reduce$49.86 - $58.72
($55.76)
$ 60.278%Reduce 0.27%176,385
TEVACharles Brandes 2014-12-31 Buy $49.86 - $58.72
($55.72)
$ 60.278%New holding3,600
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about TEVA :

    Quarterly/Annual Reports about TEVA:

      News about TEVA:

      Articles On GuruFocus.com
      Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
      Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
      Stanley Druckenmiller's Top 5 New Stocks May 25 2015 
      Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
      Teva Eyeing Mylan For $40 Billion Apr 23 2015 
      M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
      Analysts Weigh in on Auspex Pharmaceuticals Following Teva Acquisition Mar 31 2015 
      Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd Mar 27 2015 
      Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
      Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 

      More From Other Websites
      Stocks for the next decade: TEVA, CSCO & DIS May 29 2015
      Teva buying up shares of Mylan May 29 2015
      Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog May 29 2015
      Teva Enhances Extensive Women’s Health Portfolio with Launch of Generic Lomedia® 24 Fe Tablets May 29 2015
      Teva Enhances Extensive Women’s Health Portfolio with Launch of Generic Lomedia® 24 Fe Tablets May 29 2015
      FTC's Drug Settlement a Win for the Lawyers May 29 2015
      Teva, FTC Reach $1.2 Billion Settlement on Cephalon’s Provigil May 28 2015
      Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
      In Wake of Teva Deal, FTC Hopes to 'Send a Strong Signal' To Pharma May 28 2015
      Teva to pay $1.2 bn fine to settle US antitrust case May 28 2015
      With A $1.2 Billion Hammer, The FTC Closes Loophole To Prevent Generic Drugs May 28 2015
      Teva to pay $1.2 billion in drug-delay settlement May 28 2015
      Teva to pay $1.2 billion in drug-delay settlement May 28 2015
      Teva pays $1.2bn in US antitrust drugs case May 28 2015
      Teva reaches $1.2B settlement with the FTC May 28 2015
      Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
      Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
      U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil May 28 2015
      Teva agrees to $1.2B FTC anti-trust settlement May 28 2015
      Short Sellers More Selective on Big Pharma Stocks May 28 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK